Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchSargramostimSargramostim (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Sargramostim for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, November 2024, Version 1V1
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SARPAC Bosteels (RCT) -2% 1.02 [0.15-6.93] death 2/40 2/41 Improvement, RR [CI] Treatment Control SARPAC Bosteels (RCT) -20% 1.20 [0.44-3.25] ventilation 7/40 6/41 SARPAC Bosteels (RCT) -10% 1.10 [0.60-2.01] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 33% 0.67 [0.05-8.60] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 20% 0.80 [0.23-2.81] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 43% 0.57 [0.28-1.18] oxygen 40 (n) 41 (n) iLeukPulm Paine (RCT) 23% 0.77 [0.31-1.92] death 78 (n) 44 (n) iLeukPulm Paine (RCT) 15% 0.85 [0.30-2.39] death 78 (n) 44 (n) iLeukPulm Paine (RCT) 27% 0.73 [0.29-1.81] ventilation 9/78 7/44 iLeukPulm Paine (RCT) 56% 0.44 [0.21-0.90] oxygen 10/63 12/33 iLeukPulm Paine (RCT) -3% 1.03 [0.79-1.33] hosp. time 78 (n) 44 (n) Shimasaki (DB RCT) -305% 4.05 [0.20-80.9] ventilation 2/44 0/23 Shimasaki (DB RCT) -57% 1.57 [0.17-14.2] no disch. 3/44 1/23 Shimasaki (DB RCT) -12% 1.12 [0.98-1.29] no improv. 47 (n) 23 (n) Joshi (DB RCT) -30% 1.30 [0.69-2.45] progression 21/301 16/299 Joshi (DB RCT) 27% 0.73 [0.58-0.91] viral load 50 (n) 51 (n) Sargramostim COVID-19 outcomes c19early.org November 2024 Favors sargramostim Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit